http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101825385-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-308 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2300-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-536 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-539 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-752 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-536 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-752 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-539 |
| filingDate | 2015-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101825385-B1 |
| titleOfInvention | Anti-cancer Composition for Osteosarcoma Using of Extracts of the Mixture of Saururus chinensis, Scutellariae Radix, etc. |
| abstract | The present invention relates to Saururus chinensis ), golden, and chrysanthemum ( Prunella an anticancer agent composition for an osteosarcoma using an extract of a mixture of carrageenan, vulgaris , bitter gourd, and Portulaca oleracea . The anticancer composition of the present invention acts on cancer stem cells, which are the cause of the anticancer drug resistance, unlike the anticancer drugs based on the existing anticancer activity inhibitory activity, and induces its death, inhibits its proliferation and its metastasis, ยท It has the possibility of fundamental cancer treatment by blocking recurrence. Furthermore, since it does not show any toxicity to normal cells and does not affect the proliferation of normal cells, the existing cancer drug based on the killing activity of cancer cells exhibits toxicity to normal cells, Nausea, stomatitis, and the like. |
| priorityDate | 2015-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 290.